IBDEI2L0 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,41202,1,3,0)
 ;;=3^DM Type 1 w/ Unspec Compl
 ;;^UTILITY(U,$J,358.3,41202,1,4,0)
 ;;=4^E10.8
 ;;^UTILITY(U,$J,358.3,41202,2)
 ;;=^5002625
 ;;^UTILITY(U,$J,358.3,41203,0)
 ;;=E10.9^^152^2029^34
 ;;^UTILITY(U,$J,358.3,41203,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41203,1,3,0)
 ;;=3^DM Type 1 w/o Compl
 ;;^UTILITY(U,$J,358.3,41203,1,4,0)
 ;;=4^E10.9
 ;;^UTILITY(U,$J,358.3,41203,2)
 ;;=^5002626
 ;;^UTILITY(U,$J,358.3,41204,0)
 ;;=E10.620^^152^2029^5
 ;;^UTILITY(U,$J,358.3,41204,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41204,1,3,0)
 ;;=3^DM Type 1 w/ Diab Dermatitis
 ;;^UTILITY(U,$J,358.3,41204,1,4,0)
 ;;=4^E10.620
 ;;^UTILITY(U,$J,358.3,41204,2)
 ;;=^5002615
 ;;^UTILITY(U,$J,358.3,41205,0)
 ;;=E10.36^^152^2029^4
 ;;^UTILITY(U,$J,358.3,41205,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41205,1,3,0)
 ;;=3^DM Type 1 w/ Diab Cataract
 ;;^UTILITY(U,$J,358.3,41205,1,4,0)
 ;;=4^E10.36
 ;;^UTILITY(U,$J,358.3,41205,2)
 ;;=^5002602
 ;;^UTILITY(U,$J,358.3,41206,0)
 ;;=E10.621^^152^2029^6
 ;;^UTILITY(U,$J,358.3,41206,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41206,1,3,0)
 ;;=3^DM Type 1 w/ Diab Foot Ulcer
 ;;^UTILITY(U,$J,358.3,41206,1,4,0)
 ;;=4^E10.621
 ;;^UTILITY(U,$J,358.3,41206,2)
 ;;=^5002616
 ;;^UTILITY(U,$J,358.3,41207,0)
 ;;=E10.622^^152^2029^28
 ;;^UTILITY(U,$J,358.3,41207,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41207,1,3,0)
 ;;=3^DM Type 1 w/ Oth Skin Ulcer
 ;;^UTILITY(U,$J,358.3,41207,1,4,0)
 ;;=4^E10.622
 ;;^UTILITY(U,$J,358.3,41207,2)
 ;;=^5002617
 ;;^UTILITY(U,$J,358.3,41208,0)
 ;;=E10.51^^152^2029^32
 ;;^UTILITY(U,$J,358.3,41208,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41208,1,3,0)
 ;;=3^DM Type 1 w/ Periph Angiopathy w/o Gangrene
 ;;^UTILITY(U,$J,358.3,41208,1,4,0)
 ;;=4^E10.51
 ;;^UTILITY(U,$J,358.3,41208,2)
 ;;=^5002610
 ;;^UTILITY(U,$J,358.3,41209,0)
 ;;=E10.52^^152^2029^31
 ;;^UTILITY(U,$J,358.3,41209,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41209,1,3,0)
 ;;=3^DM Type 1 w/ Periph Angiopathy w/ Gangrene
 ;;^UTILITY(U,$J,358.3,41209,1,4,0)
 ;;=4^E10.52
 ;;^UTILITY(U,$J,358.3,41209,2)
 ;;=^5002611
 ;;^UTILITY(U,$J,358.3,41210,0)
 ;;=E11.00^^152^2030^19
 ;;^UTILITY(U,$J,358.3,41210,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41210,1,3,0)
 ;;=3^DM Type 2 w/ Hyperosmolarity w/o NKHHC
 ;;^UTILITY(U,$J,358.3,41210,1,4,0)
 ;;=4^E11.00
 ;;^UTILITY(U,$J,358.3,41210,2)
 ;;=^5002627
 ;;^UTILITY(U,$J,358.3,41211,0)
 ;;=E11.01^^152^2030^18
 ;;^UTILITY(U,$J,358.3,41211,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41211,1,3,0)
 ;;=3^DM Type 2 w/ Hyperosmolarity w/ Coma
 ;;^UTILITY(U,$J,358.3,41211,1,4,0)
 ;;=4^E11.01
 ;;^UTILITY(U,$J,358.3,41211,2)
 ;;=^5002628
 ;;^UTILITY(U,$J,358.3,41212,0)
 ;;=E11.21^^152^2030^7
 ;;^UTILITY(U,$J,358.3,41212,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41212,1,3,0)
 ;;=3^DM Type 2 w/ Diab Nephropathy
 ;;^UTILITY(U,$J,358.3,41212,1,4,0)
 ;;=4^E11.21
 ;;^UTILITY(U,$J,358.3,41212,2)
 ;;=^5002629
 ;;^UTILITY(U,$J,358.3,41213,0)
 ;;=E11.22^^152^2030^3
 ;;^UTILITY(U,$J,358.3,41213,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41213,1,3,0)
 ;;=3^DM Type 2 w/ Diab CKD
 ;;^UTILITY(U,$J,358.3,41213,1,4,0)
 ;;=4^E11.22
 ;;^UTILITY(U,$J,358.3,41213,2)
 ;;=^5002630
 ;;^UTILITY(U,$J,358.3,41214,0)
 ;;=E11.39^^152^2030^28
 ;;^UTILITY(U,$J,358.3,41214,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41214,1,3,0)
 ;;=3^DM Type 2 w/ Oth Diab Ophth Compl
